BioPharma Credit PLC USD · LSE:BPCP
BioPharma Credit PLC USD — BioPharma Credit — Debt Investor Presentation (January 2022)
6 slides from BioPharma Credit PLC USD's debt investor presentation, January 2022
Slide 1: Debt Capital for the Life Sciences Industry
Debt Capital for the Life Sciences Industry Investor Update – January 2022 For additional information please email: ir@bpcruk.com or visit BioPharma Credit’s website at www.bpcruk.com
Slide 2: Disclaimer
Disclaimer THIS PRESENTATION IS BEING PROVIDED TO YOU SOLELY FOR YOUR INFORMATION. THIS PRESENTATION IS NOT FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, INTO OR WITHIN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTI
Slide 3: Disclaimer
Disclaimer This presentation was prepared using the financial information available to the Company as at the date of this presentation. Except where otherwise indicated herein, the information provided in this presentation is based on matters as they exist as of the date of preparation and not as of
Slide 4: $250m senior secured corporate loan
$250m senior secured corporate loan Global Blood Therapeutics: Biopharmaceutical company focused on developing and marketing therapies for sickle cell disease Market Cap: $1,783m as of January 5 2022 Cash: $417m as of September 30 2021 ($862m PF for capital raise) LTM Sales: $180m as of Sept
Slide 5: $125m senior secured corporate loan
$125m senior secured corporate loan Evolus: Biopharmaceutical company with a customer-centric approach focused on delivering breakthrough performance beauty products Market Cap: $350m as of January 5 2022 Cash: $108m as of September 30 2021 ($183m PF for capital raise) LTM Sales: $86m as of
Slide 6: $300m senior secured corporate loan
$300m senior secured corporate loan Coherus BioSciences: Biopharmaceutical company building a leading immuno-oncology franchise funded with cash generated by its commercial biosimilars business Market Cap: $1,167m as of January 5 2022 Cash: $469m as of September 30 2021 LTM Sales: $364m as o
BioPharma Credit — Debt Investor Presentation (January 2022) on 6ix